DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT03520062

LIRAP

CompletedPhase NA

The Effect of Liraglutide on Pancreatic Hormones and Its Size

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

14

actual

Study population

Obesity / overweight

Key I/E criteria

•BMI ≥26•Male

Primary endpoint

•Volumetric Changes of the Pancreas

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03520062
Org study IDLIRAP

Timeline

Milestones

Study start2017-08-15actual
Study first posted2018-05-09actual
Primary completion2019-04-30actual
Study completion2020-01-01actual
Last update posted2020-03-24actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexMale
Healthy volunteersAccepted

Inclusion criteria

•BMI ≥ 26 og < 50 kg/m2

Exclusion criteria

•Abdominal Diameter >60cm type 1 or type 2 diabetes Heart Failure or Disease Statins Kidney or Liver disease Thyroid Disease Inflammatory Bowel Disease Gastroparesis Cancer Lung disease Psychiatric disease Gastric Bypass operation Previous pancreatitis Increased alcoholic consumption Familiar incidence of multiple endocrine neoplasia Previous treatment with GLP-1 (incretin) based medicine Pacemaker or other non-MR-compatible devices

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
3
Other (unclassified)
2
Weight & body composition
1
Glycemic / diabetes
1
Other clinical outcomes
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Changes in body weight

Time frame:6 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint/low confidence

Changes in glycemic index

Time frame:6 weeks

change from baseline, improvement

Safety / tolerability / PK

3 endpoints
Secondary/protocol endpoint

Changes in Plasma Concentrations of Pancreatic Amylase and Lipase

Time frame:6 weeks

change from baseline, descriptive

Secondary/protocol endpoint

Plasma concentrations of glucagon, insulin and citrullin

Time frame:6 weeks

concentration, descriptive

Secondary/protocol endpoint

Plasma concentrations of the drug

Time frame:6 weeks

Plasma concentration (steady state)

concentration, descriptive

Other clinical outcomes

1 endpoint
Secondary/protocol endpoint

Other MR based changes in the pancreas (edema, cellularity and structural changes)

Time frame:6 weeks

change from baseline, descriptive

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

Volumetric Changes of the Pancreas

Time frame:6 weeks

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Uptake of fluorothymidine tracer in the pancreas measured by PET

Time frame:4 weeks

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.